摘要
目的探讨原癌基因人类表皮生长因子受体2(HER2)在前列腺良恶性病变中的表达情况。方法对20例前列腺增生标本、40例前列腺癌标本及60例血清标本通过酶联免疫吸附试验(ELISA)法检测血清HER-2浓度;免疫组化法检测组织中HER-2蛋白表达。结果①60例前列腺癌、前列腺增生组织标本HER-2免疫组化染色结果均阴性;②60例血清标本中有23例可以检测出HER-2蛋白含量,其余样本均不能检测出含量。结论 HER-2在新疆地区人群中前列腺增生、前列腺癌的表达水平非常低,目前暂不能认为HER-2是治疗前列腺癌的靶点。
Objective To investigate the expression of HER -2 in benign prostatic hyperplasia, prostatic carcinoma and serum speci- mens. Methods The expression of HER - 2 were detected in 20 cases of benign prostatic hyperplasia,40 cases of prostatic carcinoma and 60 ca- ses of serum specimens by ELISA and immunohistochemistry. Results All serum samples but 23 cases were stained positively,while all of the be- nign prostatic hyperplasia and prostatic carcinoma tissues were stained negatively. Conclusion HER - 2 may be not a target for the treatment of prostate cancer in xinjiang.
出处
《临床和实验医学杂志》
2014年第3期177-180,共4页
Journal of Clinical and Experimental Medicine
关键词
前列腺增生
前列腺癌
HER-2
Benign prostatic hyperplasia
Prostate cancer
HER - 2
